The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer.
ALK
ALK variant
BIM
crizotinib
non-small cell lung cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
06
2019
accepted:
27
08
2019
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
15
10
2019
Statut:
epublish
Résumé
Patients' clinical factors and genetics factors such as anaplastic lymphoma kinase (ALK) fusion variants and BIM (Bcl-2-like 11) polymorphism were reported to be associated with clinical outcome in crizotinib-treated advanced non-small cell lung cancer (NSCLC). However, the results were still controversial. We analyzed outcome of 54 patients with known ALK fusion variants who received crizotinib for advanced NSCLC. Thirty of them had successful BIM polymorphism analysis and 6 (20%) had a BIM deletion. Multivariate Cox regression analysis found that previous anticancer therapy [adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI), 1.04-1.76 for each additional line of therapy,
Identifiants
pubmed: 31608224
doi: 10.3389/fonc.2019.00880
pmc: PMC6768009
doi:
Types de publication
Journal Article
Langues
eng
Pagination
880Informations de copyright
Copyright © 2019 Lin, Liu and Shih.
Références
Cell Res. 2018 Jun;28(6):693-695
pubmed: 29628502
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Oncol. 2014 Apr;9(4):483-7
pubmed: 24736070
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Lung Cancer. 2016 Jul;97:43-7
pubmed: 27237026
Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53
pubmed: 18583573
Lung Cancer. 2018 Apr;118:128-133
pubmed: 29571990
Oncotarget. 2016 Dec 20;7(51):84666-84674
pubmed: 27835868
BMC Cancer. 2018 Jan 3;18(1):10
pubmed: 29298713
Clin Cancer Res. 2012 Sep 1;18(17):4682-90
pubmed: 22912387
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5195-200
pubmed: 24706829
PLoS One. 2014 Dec 12;9(12):e114008
pubmed: 25501361
J Natl Cancer Inst. 1980 Jul;65(1):25-32
pubmed: 6930515
Ann Oncol. 2013 Aug;24(8):2080-7
pubmed: 23559152
J Thorac Oncol. 2018 Oct;13(10):1539-1548
pubmed: 29966800
Korean J Intern Med. 2019 Sep;34(5):1116-1124
pubmed: 29950554
Nat Med. 2012 Mar 18;18(4):521-8
pubmed: 22426421
JAMA Oncol. 2016 Jun 1;2(6):826-8
pubmed: 27077907
PLoS One. 2016 Sep 16;11(9):e0160752
pubmed: 27637025
Int J Cancer. 2018 Jun 15;142(12):2589-2598
pubmed: 29363116
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
J Clin Oncol. 2016 Oct 1;34(28):3383-9
pubmed: 27354483
J Thorac Dis. 2015 Jul;7(7):1181-8
pubmed: 26380734
Ann Oncol. 2017 Apr 1;28(4):791-797
pubmed: 28039177
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Clin Lung Cancer. 2016 May;17(3):223-31
pubmed: 26454342
J Clin Oncol. 2018 Apr 20;36(12):1199-1206
pubmed: 29373100
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Biochimie. 2018 Nov;154:19-24
pubmed: 30071258
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
J Thorac Dis. 2017 Jul;9(7):1903-1910
pubmed: 28839988
Clin Cancer Res. 2014 Apr 15;20(8):2029-34
pubmed: 24573551
Cell Mol Life Sci. 2016 Mar;73(6):1209-24
pubmed: 26755435
J Transl Med. 2016 Oct 19;14(1):296
pubmed: 27756333
Int J Clin Oncol. 2015 Aug;20(4):668-73
pubmed: 25343946
Cancer. 2017 Aug 1;123(15):2927-2935
pubmed: 28346673
Clin Lung Cancer. 2016 Sep;17(5):e77-e94
pubmed: 27130468